VX-702

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Rheumatoid Arthritis

Phase 2

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

CompletedNCT00205478

Vertex Pharmaceuticals IncorporatedRheumatoid Arthritis

Start: 2005-06-30End: 2006-02-28Target: 300Updated: 2007-12-07

A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

CompletedNCT00395577

Vertex Pharmaceuticals IncorporatedRheumatoid Arthritis

Start: 2006-11-30End: 2007-07-31Target: 120Updated: 2007-12-07